CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: To further determine the effect of CD8 blockade on LSCs in H2–/– CML, αCD8 mAb– or control IgG–treated H2–/– CML mice were sacrificed 16 days after CML induction, and BM was analyzed.